HopeStage
Back to all studies
CompletedNCT00083954

Quetiapine versus placebo for depression in bipolarity

About this title

Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression

Read the official source — NCT00083954
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Birmingham and 35 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJune 2004
Recruitment status
Completed
Enrollment listed in the registry
530
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00083954
Official title
Show the full official title

A Confirmatory Multicenter, Double-blind, Randomized, Placebo Controlled Study of the Use of Quetiapine Fumarate (SEROQUEL) in the Treatment of Patients With Bipolar Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Birmingham · Scottsdale · Cerritos

33 more locations
  • Garden Grove
  • San Diego
  • Torrance
  • Jacksonville
  • Maitland
  • Orlando
  • Winter Park
  • Boise
  • Oak Brook
  • Overbrook Terrace
  • Shreveport
  • Baltimore
  • Clementon
  • Moorestown
  • Albuquerque
  • Brooklyn
  • New York
  • Staten Island
  • Raleigh
  • Cincinnati
  • Dayton
  • Oklahoma City
  • Portland
  • Philadelphia
  • Pittsburgh
  • Charleston
  • Memphis
  • Austin
  • Houston
  • Salt Lake City
  • Bellevue
  • Kirkland
  • Seattle

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is AstraZeneca.

Did this study involve medication?

Yes. The study involved medication, including Quetiapine Fumarate.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies